Barclays
ELDN icon

Barclays’s Eledon Pharmaceuticals ELDN Stock Holding History

Barclays’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$46.8K Sell
11,889
-1,927
-14% -$7.01K ﹤0.01% 4339
2026
Q1 		$42.6K Sell
13,816
-73,656
-84% -$173K ﹤0.01% 4380
2025
Q4 		$132K Buy
87,472
+7,719
+10% +$18.3K ﹤0.01% 4493
2025
Q3 		$207K Sell
79,753
-22,125
-22% -$64.7K ﹤0.01% 4272
2025
Q2 		$276K Buy
101,878
+31,878
+46% +$95.6K ﹤0.01% 4086
2025
Q1 		$237K Hold
70,000
– – ﹤0.01% 3947
2024
Q4 		$288K Buy
+70,000
New +$276K ﹤0.01% 4137
2019
Q2 		– Sell
-4
Closed – – 7007
2019
Q1 		$0 Buy
+4
New +$265 ﹤0.01% 7077
2018
Q4 		– Hold
0
– – – 7032
2018
Q3 		– Hold
0
– – – 7192
2018
Q2 		– Sell
-1
Closed -$103 – 7034
2018
Q1 		$0 Buy
+1
New +$74 ﹤0.01% 7123
2017
Q4 		– Hold
0
– – – 6962
2017
Q3 		– Sell
-3
Closed -$249 – 6890
2017
Q2 		$0 Sell
3
-73
-96% -$7.44K ﹤0.01% 6708
2017
Q1 		$10K Buy
76
+51
+204% +$7.49K ﹤0.01% 6069
2016
Q4 		$4K Buy
25
+19
+317% +$3.64K ﹤0.01% 6182
2016
Q3 		$1K Buy
6
+4
+200% +$1.46K ﹤0.01% 6381
2016
Q2 		$2K Buy
2
+1
+100% +$1.1K ﹤0.01% 5943
2016
Q1 		$1K Sell
1
-2
-67% -$1.96K ﹤0.01% 5956
2015
Q4 		$4K Buy
+3
New +$5.23K ﹤0.01% 5612
2015
Q3 		– Sell
-1
Closed -$2.06K – 6878
2015
Q2 		$2K Hold
1
– – ﹤0.01% 6790
2015
Q1 		$2K Sell
1
-2
-67% -$4.41K ﹤0.01% 6860
2014
Q4 		$7K Buy
+3
New +$7.12K ﹤0.01% 6875

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ZP
Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return

Barclays's ELDN Position: Q2 2026 in Review

Barclays reduced its Eledon Pharmaceuticals (ELDN) stake by 14% in Q2 2026, selling an estimated $7.01K and leaving 11,889 shares worth $46.8K. The position accounts for ﹤0.01% of the portfolio, ranked #4339.

Barclays first reported a position in ELDN in Q4 2014 and has held it in 19 quarters since. The position peaked at $288K in Q4 2024. 161 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

  • Barclays held 11,889 shares of Eledon Pharmaceuticals worth $46.8K as of Q2 2026.
  • Barclays sold 1,927 Eledon Pharmaceuticals shares in Q2 2026, an estimated $7.01K.
  • Eledon Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4339 holding.
  • Barclays first reported a position in Eledon Pharmaceuticals in Q4 2014 and has held it in 19 quarters since.
  • Barclays's Eledon Pharmaceuticals position peaked at $288K in Q4 2024.
  • 161 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.